A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

ClinicalTrials.gov ID: NCT00546715

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00546715. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection

Study identification

NCT ID: NCT00546715
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 95 participants

Conditions and interventions

Conditions

Chronic Hepatitis C

Interventions

Daclatasvir Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 49 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2007 (Type not available)
Primary completion: May 2008 (Actual)
Completion: May 2008 (Actual)
Last update posted: Nov 18, 2015

2007 – 2008

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Advanced Clinical Research Institute	Anaheim	California	92801	—
Orlando Clinical Research Center	Orlando	Florida	32809	—
Parexel International Corporation	Baltimore	Maryland	21225	—
Mayo Clinic	Rochester	Minnesota	55905	—
Bristol-Myers Squibb Clinical Pharmacology Unit	Hamilton	New Jersey	08690	—
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	—
University Of Virginia Digestive Health Center Of Excellence	Charlottesville	Virginia	22908	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00546715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 18, 2015 · Synced Nov 15, 2026